Suppr超能文献

[使用RU 41740对3008名儿童复发性呼吸道感染进行预防性治疗]

[The preventive treatment of recurring respiratory infections using RU 41740 in 3,008 children].

作者信息

Bellon G, Ounis I

机构信息

Centre Hospitalier Lyon Sud, Sainte-Eugénie, Pierre-Bénite.

出版信息

Ann Pediatr (Paris). 1990 Oct;37(8):535-40.

PMID:2264700
Abstract

Biostim is an immunomodulating agent of biologic origin indicated for the prophylactic treatment of recurrent respiratory tract infections in adults and children over one year of age. It has been proved effective by double-blind placebo-controlled trials. This study was undertaken to evaluate the value and tolerance of Biostim in a large number of patients under the conditions of actual use. Three thousand and eight patients were included in the study. At inclusion, 93.7% of patients had a history of recurrent ENT infections (6.27 +/- 3.04 episodes during the previous year). After three months follow-up, results were considered good by the investigator in 75.8% of cases; 75.3% of the children had either no infection or only one infection during the three months follow-up. Results were not influenced by age and/or a history of allergy.

摘要

必思添是一种生物源免疫调节剂,适用于预防一岁以上成人和儿童复发性呼吸道感染。双盲安慰剂对照试验已证明其有效。本研究旨在评估必思添在实际使用条件下对大量患者的疗效和耐受性。该研究纳入了3008名患者。纳入研究时,93.7%的患者有耳鼻喉反复感染史(前一年6.27±3.04次发作)。经过三个月的随访,研究者认为75.8%的病例结果良好;75.3%的儿童在三个月随访期间未发生感染或仅发生一次感染。结果不受年龄和/或过敏史的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验